Cargando…
Formalizing drug indications on the road to therapeutic intent
Therapeutic intent, the reason behind the choice of a therapy and the context in which a given approach should be used, is an important aspect of medical practice. There are unmet needs with respect to current electronic mapping of drug indications. For example, the active ingredient sildenafil has...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259666/ https://www.ncbi.nlm.nih.gov/pubmed/29016968 http://dx.doi.org/10.1093/jamia/ocx064 |
_version_ | 1783374729465298944 |
---|---|
author | Nelson, Stuart J Oprea, Tudor I Ursu, Oleg Bologa, Cristian G Zaveri, Amrapali Holmes, Jayme Yang, Jeremy J Mathias, Stephen L Mani, Subramani Tuttle, Mark S Dumontier, Michel |
author_facet | Nelson, Stuart J Oprea, Tudor I Ursu, Oleg Bologa, Cristian G Zaveri, Amrapali Holmes, Jayme Yang, Jeremy J Mathias, Stephen L Mani, Subramani Tuttle, Mark S Dumontier, Michel |
author_sort | Nelson, Stuart J |
collection | PubMed |
description | Therapeutic intent, the reason behind the choice of a therapy and the context in which a given approach should be used, is an important aspect of medical practice. There are unmet needs with respect to current electronic mapping of drug indications. For example, the active ingredient sildenafil has 2 distinct indications, which differ solely on dosage strength. In progressing toward a practice of precision medicine, there is a need to capture and structure therapeutic intent for computational reuse, thus enabling more sophisticated decision-support tools and a possible mechanism for computer-aided drug repurposing. The indications for drugs, such as those expressed in the Structured Product Labels approved by the US Food and Drug Administration, appears to be a tractable area for developing an application ontology of therapeutic intent. |
format | Online Article Text |
id | pubmed-6259666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62596662018-12-03 Formalizing drug indications on the road to therapeutic intent Nelson, Stuart J Oprea, Tudor I Ursu, Oleg Bologa, Cristian G Zaveri, Amrapali Holmes, Jayme Yang, Jeremy J Mathias, Stephen L Mani, Subramani Tuttle, Mark S Dumontier, Michel J Am Med Inform Assoc Perspective Therapeutic intent, the reason behind the choice of a therapy and the context in which a given approach should be used, is an important aspect of medical practice. There are unmet needs with respect to current electronic mapping of drug indications. For example, the active ingredient sildenafil has 2 distinct indications, which differ solely on dosage strength. In progressing toward a practice of precision medicine, there is a need to capture and structure therapeutic intent for computational reuse, thus enabling more sophisticated decision-support tools and a possible mechanism for computer-aided drug repurposing. The indications for drugs, such as those expressed in the Structured Product Labels approved by the US Food and Drug Administration, appears to be a tractable area for developing an application ontology of therapeutic intent. Oxford University Press 2017-11 2017-07-17 /pmc/articles/PMC6259666/ /pubmed/29016968 http://dx.doi.org/10.1093/jamia/ocx064 Text en © The Author 2017. Published by Oxford University Press on behalf of the American Medical Informatics Association. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Perspective Nelson, Stuart J Oprea, Tudor I Ursu, Oleg Bologa, Cristian G Zaveri, Amrapali Holmes, Jayme Yang, Jeremy J Mathias, Stephen L Mani, Subramani Tuttle, Mark S Dumontier, Michel Formalizing drug indications on the road to therapeutic intent |
title | Formalizing drug indications on the road to therapeutic intent |
title_full | Formalizing drug indications on the road to therapeutic intent |
title_fullStr | Formalizing drug indications on the road to therapeutic intent |
title_full_unstemmed | Formalizing drug indications on the road to therapeutic intent |
title_short | Formalizing drug indications on the road to therapeutic intent |
title_sort | formalizing drug indications on the road to therapeutic intent |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259666/ https://www.ncbi.nlm.nih.gov/pubmed/29016968 http://dx.doi.org/10.1093/jamia/ocx064 |
work_keys_str_mv | AT nelsonstuartj formalizingdrugindicationsontheroadtotherapeuticintent AT opreatudori formalizingdrugindicationsontheroadtotherapeuticintent AT ursuoleg formalizingdrugindicationsontheroadtotherapeuticintent AT bologacristiang formalizingdrugindicationsontheroadtotherapeuticintent AT zaveriamrapali formalizingdrugindicationsontheroadtotherapeuticintent AT holmesjayme formalizingdrugindicationsontheroadtotherapeuticintent AT yangjeremyj formalizingdrugindicationsontheroadtotherapeuticintent AT mathiasstephenl formalizingdrugindicationsontheroadtotherapeuticintent AT manisubramani formalizingdrugindicationsontheroadtotherapeuticintent AT tuttlemarks formalizingdrugindicationsontheroadtotherapeuticintent AT dumontiermichel formalizingdrugindicationsontheroadtotherapeuticintent |